PHILIPPE DUCHATEAU

About PHILIPPE DUCHATEAU

Philippe Duchateau, Ph.D., is a key scientific leader at Cellectis, where he has served as Chief Scientific Officer since 2012. He joined the company in 2001 to help pioneer its early genome-editing programs, at a time when gene editing was still an emerging field. Since 2004, he has led Cellectis’ Research department, making him one of the main scientific architects behind the group’s innovation strategy. His academic and international background gave him deep expertise in molecular biology, genetic engineering, and genome-editing technologies. Before joining Cellectis, Philippe Duchateau earned a Ph.D. in biochemistry and molecular biology from the Institut Pasteur in Lille in 1993. He then completed an extended postdoctoral fellowship from 1993 to 2001 at the Cardiovascular Research Institute of the University of California, San Francisco. That experience in the United States strengthened his ability to work in highly demanding research environments and on cutting-edge scientific topics. At Cellectis, he played a central role in the development of the company’s foundational technologies, particularly those related to gene editing and the therapeutic application of allogeneic CAR-T cells. His responsibilities have been instrumental in shaping Cellectis’ scientific expertise around TALEN® technology and cell-engineering approaches designed to create innovative treatments for cancer and certain genetic diseases. Philippe Duchateau has also contributed to the scientific visibility of the company through major publications and presentations focused on improving the safety, precision, and efficacy of CAR-T cells. His work reflects a strong translational orientation, bridging fundamental research, preclinical proof of concept, and therapeutic development. Overall, his profile combines scientific depth, international research experience, and a long-standing leadership role within a listed biotechnology company recognized for its genome-editing capabilities.